COVID - 19大流行:管理和挑战

Parisa Saberi-Hasanabadi, H. Mohammadi
{"title":"COVID - 19大流行:管理和挑战","authors":"Parisa Saberi-Hasanabadi, H. Mohammadi","doi":"10.18502/pbr.v7i2.7359","DOIUrl":null,"url":null,"abstract":"Background: Coronavirus Disease 2019 (COVID-19) is an ongoing pandemic caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‑CoV‑2). The outbreak was first identified in Wuhan, China, in December 2019. \nObjectives: This review gives a bird’s-eye view of the COVID-19 pandemic and its various effects on human society. Since knowledge about this virus is rapidly evolving, readers are urged to update themselves regularly. \nMethods: In this review, our searching was performed on international databases of Embase, ScienceDirect, Scopus, PubMed, and Web of Science (ISI) from October 2019 to June 2020. \nResults: Most patients infected with COVID‑19 have mild symptoms. Approximately 15% of patients have severe pneumonia, and about 5% acute distress syndrome or organ failure. In the absence of definitive treatment and vaccines, the most effective measure is to prevent infection, particularly in those at high risk of taking the severe form of the disease with adverse outcomes. Pharmacotherapy is essentially supportive; the role of antiviral agents is yet to be established. The commonest drugs used in treating this viral disease are tocilizumab, remdesivir, favipiravir, and camostat mesilate. Also, drugs related to malaria, AIDS, and Ebola, such as hydroxychloroquine, are widely used. Based on physical examinations alone, it is impossible to comment with certainty in mild cases of the disease. Accordingly, a wide range of methods is used for diagnosing and treating the disease. Various variables in reducing the severity of the epidemic and the effects of the virus require special management at the national, regional, and global levels. \nConclusion: This review summarizes the latest findings in safety, management, and public services related to the COVID-19 virus epidemic.","PeriodicalId":6323,"journal":{"name":"2005 Asian Conference on Sensors and the International Conference on New Techniques in Pharmaceutical and Biomedical Research","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"COVID‐19 Pandemic: Management and Challenges\",\"authors\":\"Parisa Saberi-Hasanabadi, H. Mohammadi\",\"doi\":\"10.18502/pbr.v7i2.7359\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Coronavirus Disease 2019 (COVID-19) is an ongoing pandemic caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‑CoV‑2). The outbreak was first identified in Wuhan, China, in December 2019. \\nObjectives: This review gives a bird’s-eye view of the COVID-19 pandemic and its various effects on human society. Since knowledge about this virus is rapidly evolving, readers are urged to update themselves regularly. \\nMethods: In this review, our searching was performed on international databases of Embase, ScienceDirect, Scopus, PubMed, and Web of Science (ISI) from October 2019 to June 2020. \\nResults: Most patients infected with COVID‑19 have mild symptoms. Approximately 15% of patients have severe pneumonia, and about 5% acute distress syndrome or organ failure. In the absence of definitive treatment and vaccines, the most effective measure is to prevent infection, particularly in those at high risk of taking the severe form of the disease with adverse outcomes. Pharmacotherapy is essentially supportive; the role of antiviral agents is yet to be established. The commonest drugs used in treating this viral disease are tocilizumab, remdesivir, favipiravir, and camostat mesilate. Also, drugs related to malaria, AIDS, and Ebola, such as hydroxychloroquine, are widely used. Based on physical examinations alone, it is impossible to comment with certainty in mild cases of the disease. Accordingly, a wide range of methods is used for diagnosing and treating the disease. Various variables in reducing the severity of the epidemic and the effects of the virus require special management at the national, regional, and global levels. \\nConclusion: This review summarizes the latest findings in safety, management, and public services related to the COVID-19 virus epidemic.\",\"PeriodicalId\":6323,\"journal\":{\"name\":\"2005 Asian Conference on Sensors and the International Conference on New Techniques in Pharmaceutical and Biomedical Research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-10-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"2005 Asian Conference on Sensors and the International Conference on New Techniques in Pharmaceutical and Biomedical Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.18502/pbr.v7i2.7359\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"2005 Asian Conference on Sensors and the International Conference on New Techniques in Pharmaceutical and Biomedical Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18502/pbr.v7i2.7359","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

背景:2019冠状病毒病(COVID-19)是由严重急性呼吸综合征冠状病毒2 (SARS‑CoV‑2)引起的持续大流行。该疫情于2019年12月在中国武汉首次被发现。目的:概述新冠肺炎大流行及其对人类社会的各种影响。由于有关这种病毒的知识正在迅速发展,因此敦促读者定期更新自己。方法:在本综述中,我们检索了Embase、ScienceDirect、Scopus、PubMed和Web of Science (ISI)等国际数据库,检索时间为2019年10月至2020年6月。结果:大多数感染COVID - 19的患者症状轻微。约15%的患者患有严重肺炎,约5%的患者患有急性窘迫综合征或器官衰竭。在缺乏明确治疗和疫苗的情况下,最有效的措施是预防感染,特别是在那些极有可能患上严重形式的疾病并产生不良后果的人群中。药物治疗基本上是支持性的;抗病毒药物的作用尚未确定。治疗这种病毒性疾病最常用的药物是托珠单抗、瑞德西韦、法匹拉韦和甲巯咪唑他酯。此外,羟氯喹等与疟疾、艾滋病、埃博拉有关的药物也被广泛使用。仅根据体格检查,不可能对病情轻微的病例作出肯定的评论。因此,广泛的方法被用于诊断和治疗该疾病。在减少流行病的严重程度和病毒的影响方面存在各种变数,需要在国家、区域和全球各级进行特别管理。结论:本文综述了2019冠状病毒病疫情安全、管理和公共服务方面的最新研究成果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
COVID‐19 Pandemic: Management and Challenges
Background: Coronavirus Disease 2019 (COVID-19) is an ongoing pandemic caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‑CoV‑2). The outbreak was first identified in Wuhan, China, in December 2019. Objectives: This review gives a bird’s-eye view of the COVID-19 pandemic and its various effects on human society. Since knowledge about this virus is rapidly evolving, readers are urged to update themselves regularly. Methods: In this review, our searching was performed on international databases of Embase, ScienceDirect, Scopus, PubMed, and Web of Science (ISI) from October 2019 to June 2020. Results: Most patients infected with COVID‑19 have mild symptoms. Approximately 15% of patients have severe pneumonia, and about 5% acute distress syndrome or organ failure. In the absence of definitive treatment and vaccines, the most effective measure is to prevent infection, particularly in those at high risk of taking the severe form of the disease with adverse outcomes. Pharmacotherapy is essentially supportive; the role of antiviral agents is yet to be established. The commonest drugs used in treating this viral disease are tocilizumab, remdesivir, favipiravir, and camostat mesilate. Also, drugs related to malaria, AIDS, and Ebola, such as hydroxychloroquine, are widely used. Based on physical examinations alone, it is impossible to comment with certainty in mild cases of the disease. Accordingly, a wide range of methods is used for diagnosing and treating the disease. Various variables in reducing the severity of the epidemic and the effects of the virus require special management at the national, regional, and global levels. Conclusion: This review summarizes the latest findings in safety, management, and public services related to the COVID-19 virus epidemic.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Antibacterial Activities and Chemical Compounds of Plantago lanceolata (Ribwort Plantain) and Plantago major (Broadleaf Plantain) Leaf Extracts Effectiveness of 5-aminolevulinic Acid-mediated Photodynamic Therapy Combined With Curcumin Drug-related Problems Among Type 2 Diabetic Patients With Hypertension in a Tertiary Care Hospital in Lebanon: A Cross-sectional Study The Efficacy and Safety of Adding Chlorpromazine to Atazanavir/Ritonavir Regimen in the Treatment of Moderate COVID-19 Patients, a Randomized Double-blind Clinical Trial Acetylcholinesterase Inhibitory Activity of Standardized Cannabinoids-rich Fractions
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1